Company news
Rallybio Corporation (NASDAQ:RLYB) news
Rallybio Corporation news releases on 6ix. Latest, Nov 2, 2023: Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation…
Press releases — page 2
Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting
November 1, 2023
Rallybio to Present at the JonesTrading 2023 Healthcare Summit
October 2, 2023
Rallybio Presents Phase 1 Single Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
September 2, 2023
Rallybio to Present at Upcoming Investor Conferences in September
August 30, 2023
Rallybio Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 7, 2023
Rallybio to Present at the 2023 Wedbush PacGrow Healthcare Conference
August 1, 2023
Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW)
July 10, 2023
Rallybio Announces Succession Plan; Appoints Stephen Uden, M.D., as Chief Executive Officer, Effective August 1, 2023
June 28, 2023
Rallybio Announces Proof-of-Concept Results and Development Updates for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia
June 23, 2023
Rallybio to Present Data from the RLYB212 Phase 1b Proof-of-Concept Study at the 31st Congress of the International Society on Thrombosis and Haemostasis
June 8, 2023
Rallybio to Present at the Jefferies Healthcare Conference
May 31, 2023
Rallybio Reports First Quarter 2023 Financial Results
May 8, 2023
Rallybio to Present at the JMP Securities 2023 Life Sciences Conference
May 7, 2023
Rallybio Announces Clinical Proof-of-Concept Results for RLYB211, an Anti-HPA-1a Polyclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), Published in the Journal of Thrombosis and Haemostasis
April 5, 2023
Rallybio Announces Acceptance of Abstract for RLYB212 at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH)
April 2, 2023
Rallybio Reports Fourth Quarter and Full Year 2022 Financial Results
March 5, 2023
Rallybio Announces Proof-of-Concept Achieved for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia
March 5, 2023
Rallybio to Present at Upcoming Investor Conferences in March
February 28, 2023
EyePoint and Rallybio Announce Research Collaboration to Evaluate Rallybio’s Inhibitor of Complement Component 5 (C5) and EyePoint’s Proprietary Durasert® Technology for Sustained Intraocular Delivery in Geographic Atrophy
February 26, 2023
Rallybio Announces Appointment of Jonathan I. Lieber as Chief Financial Officer
January 30, 2023
Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2023
January 4, 2023
Rallybio Announces Publication of Data Highlighting the Ability of HPA-1a-Specific Antibodies to Prevent Alloimmunization in an Authentic Mouse Model of FNAIT
December 14, 2022
AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases
November 30, 2022
Rallybio Announces Proposed Public Offering
November 9, 2022
Rallybio Announces Pricing of $50 Million Public Offering
November 9, 2022
Rallybio Reports Third Quarter 2022 Financial Results
November 6, 2022
Rallybio Announces Positive Phase 1 Single Ascending Dose Results for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
November 6, 2022
Rallybio Announces Positive Preliminary Results for RLYB212, an anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia
September 27, 2022
Rallybio Reports Second Quarter 2022 Financial Results
August 7, 2022
Rallybio Appoints Wendy K. Chung, M.D., Ph.D., to Its Board of Directors
August 1, 2022
Rallybio Announces Retirement of Jeffrey Fryer, CPA, Chief Financial Officer
June 1, 2022
Rallybio Reports First Quarter 2022 Financial Results
May 9, 2022
Rallybio Announces In-Licensing of Potential First-In-Class Preclinical Antibody Candidate from Sanofi
May 9, 2022
Rallybio Appoints Christine A. Nash and Hui Liu, Ph.D., to Its Board of Directors
April 3, 2022
Rallybio Reports Fourth Quarter and Full Year 2021 Financial Results
March 14, 2022
Rallybio Reports Positive Data in Its Clinical Program for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
November 30, 2021
Rallybio Corporation Reports Third Quarter 2021 Financial Results and Recent Business Highlights
November 9, 2021
Rallybio Corporation Reports Second Quarter 2021 Financial Results and Recent Business Highlights
September 8, 2021
Rallybio Corporation Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
August 1, 2021
Rallybio Corporation Announces Pricing of Initial Public Offering
July 27, 2021